Ameritas Investment Partners Inc. Purchases Shares of 8,451 CRISPR Therapeutics AG $CRSP

Ameritas Investment Partners Inc. acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 8,451 shares of the company’s stock, valued at approximately $411,000.

Other hedge funds have also modified their holdings of the company. SVB Wealth LLC acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth $25,000. Costello Asset Management INC purchased a new position in CRISPR Therapeutics in the 1st quarter worth about $27,000. Atlantic Union Bankshares Corp acquired a new stake in CRISPR Therapeutics during the 2nd quarter worth about $33,000. Quantbot Technologies LP lifted its stake in CRISPR Therapeutics by 272.4% during the first quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock valued at $45,000 after buying an additional 978 shares in the last quarter. Finally, IFP Advisors Inc boosted its holdings in shares of CRISPR Therapeutics by 24.6% in the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after buying an additional 181 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 50,895 shares of the firm’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the transaction, the chief executive officer owned 254,201 shares in the company, valued at approximately $17,262,789.91. This trade represents a 16.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. The trade was a 1.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 56,213 shares of company stock worth $3,810,458. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on CRSP. Wedbush dropped their target price on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 5th. Citigroup reiterated a “buy” rating and set a $77.00 price objective (down from $87.00) on shares of CRISPR Therapeutics in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada raised their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 11th. Finally, Bank of America upped their price target on CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Eleven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $67.42.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $53.63 on Friday. The business’s 50-day moving average price is $61.92 and its two-hundred day moving average price is $54.74. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $78.48. The company has a market capitalization of $5.11 billion, a P/E ratio of -9.59 and a beta of 1.89.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. The company had revenue of $0.89 million during the quarter, compared to the consensus estimate of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.